The management of gastric adenocarcinoma with postoperative chemoirradiation. A non-randomized comparison of oral UFT and 5-FU

Tumori

Volumn 94, Issue 1, 2008, Pages 70-74

  Surenkok, Serdar ^a   Beyzadeoglu, Murat ^a   Oysul, Kaan ^a   Ozyigit, Gokhan ^a   Ataergin, Selmin ^a   Arpaci, Fikret ^a   Ozet, Ahmet ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

5 fluorouracil; Chemotherapy; Combined modality therapy; Gastric carcinoma; Oral UFT (tegafur uracil); Radiotherapy

Indexed keywords

COBALT 60; FLUOROURACIL; FOLINIC ACID; UFT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; MALE; OVERALL SURVIVAL; POSTOPERATIVE CARE; RADIATION DOSE; STOMACH ADENOCARCINOMA; SURGICAL APPROACH; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 41749112628     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400113     Document Type: Article

References (11)

1. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA: Combined 5-fluorouracil and supervoltage irradiation therapy of locally unresectable gastrointestinal cancer. Lancet, 2: 865-867, 1969.
2. MacDonald J, Smalley S, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 345: 725-730, 2001.
3. Ravaud A, Borner M, Schellens JHM, Geoffrois L, Schöffski BP, Kroon K, Wanders J, Hanauske AR, Fumoleau P: UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research and Treatment of Cancer (EORTC) phase II trial. Eur J Cancer, 37: 1642-1647, 2001.
4. Kim YH, Cheong SK, Lee JD, Park JS, Shin SW, Kim JS: Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol, 19: 212-216, 1996.
5. Kim YH, Shin SW, Kim BS, Park YT, Kim JG, Kim JS: A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology, 11: 119-123, 1997.
6. Sato A, Kurihara M, Koizumi W, Takeda Y, Fukuyama A: A phase II study of UFT plus cisplatin (UFTP) therapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol, 19: 279a (Abstr 1087), 2000.
7. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, Yaosaka T, Takahashi H, Ito T, Sasai T: A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res, 82: 613-620, 1991.
8. Feliu J, Gonzalez Baron M, Garcia Giron C, Espinosa E, Vicent JM, Gomez Navarro J, Berrocal A, Ordonez A, Vilches Y, de Castro J, Diaz J: Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ cooperative group. Cancer, 78: 211-216, 1996.
9. Kim YH, Kim BS, Seo JH, Choi CW, Kim JS, Chun HJ, Hyun JH, Kim JS: Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma. Oncology, 13: 64-68, 1999.
10. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer, 79: 1522-1530, 1999.
11. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet, 345: 745-748, 1995.